Fendler Annika, Au Lewis, Shepherd Scott T C, Byrne Fiona, Cerrone Maddalena, Boos Laura Amanda, Rzeniewicz Karolina, Gordon William, Shum Ben, Gerard Camille L, Ward Barry, Xie Wenyi, Schmitt Andreas M, Joharatnam-Hogan Nalinie, Cornish Georgina H, Pule Martin, Mekkaoui Leila, Ng Kevin W, Carlyle Eleanor, Edmonds Kim, Del Rosario Lyra, Sarker Sarah, Lingard Karla, Mangwende Mary, Holt Lucy, Ahmod Hamid, Stone Richard, Gomes Camila, Flynn Helen R, Agua-Doce Ana, Hobson Philip, Caidan Simon, Howell Michael, Wu Mary, Goldstone Robert, Crawford Margaret, Cubitt Laura, Patel Harshil, Gavrielides Mike, Nye Emma, Snijders Ambrosius P, MacRae James I, Nicod Jerome, Gronthoud Firza, Shea Robyn L, Messiou Christina, Cunningham David, Chau Ian, Starling Naureen, Turner Nicholas, Welsh Liam, van As Nicholas, Jones Robin L, Droney Joanne, Banerjee Susana, Tatham Kate C, Jhanji Shaman, O'Brien Mary, Curtis Olivia, Harrington Kevin, Bhide Shreerang, Bazin Jessica, Robinson Anna, Stephenson Clemency, Slattery Tim, Khan Yasir, Tippu Zayd, Leslie Isla, Gennatas Spyridon, Okines Alicia, Reid Alison, Young Kate, Furness Andrew J S, Pickering Lisa, Gandhi Sonia, Gamblin Steve, Swanton Charles, Nicholson Emma, Kumar Sacheen, Yousaf Nadia, Wilkinson Katalin A, Swerdlow Anthony, Harvey Ruth, Kassiotis George, Larkin James, Wilkinson Robert J, Turajlic Samra
Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.
Equal contribution.
Res Sq. 2021 Sep 20:rs.3.rs-916427. doi: 10.21203/rs.3.rs-916427/v1.
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study (NCT03226886) integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2-positive, 94 were symptomatic and 2 patients died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies, 82% had neutralizing antibodies against WT, whereas neutralizing antibody titers (NAbT) against the Alpha, Beta, and Delta variants were substantially reduced. Whereas S1-reactive antibody levels decreased in 13% of patients, NAbT remained stable up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment-specific, but presented compensatory cellular responses, further supported by clinical. Overall, these findings advance the understanding of the nature and duration of immune response to SARS-CoV-2 in patients with cancer.
癌症患者感染新冠病毒后的发病率和死亡率更高。在此，我们展示了前瞻性CAPTURE研究（NCT03226886），该研究将纵向免疫分析与临床注释相结合。在357名癌症患者中，118人新冠病毒检测呈阳性，94人出现症状，2名患者死于新冠病毒感染。在这个队列中，83%的患者有S1反应性抗体，82%的患者有针对野生型的中和抗体，而针对阿尔法、贝塔和德尔塔变异株的中和抗体滴度（NAbT）则大幅降低。虽然13%的患者S1反应性抗体水平下降，但NAbT在长达329天的时间内保持稳定。患者还可检测到新冠病毒特异性T细胞，且CD4 +反应与S1反应性抗体水平相关，尽管血液系统恶性肿瘤患者的免疫反应受损，具有疾病和治疗特异性，但仍表现出代偿性细胞反应，临床研究进一步证实了这一点。总体而言，这些发现增进了我们对癌症患者针对新冠病毒免疫反应的性质和持续时间的理解。
